ESOPHAGEAL ADENOCARCINOMA (EAC)
Clinical trials for ESOPHAGEAL ADENOCARCINOMA (EAC) explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGEAL ADENOCARCINOMA (EAC) trials appear
Sign up with your email to follow new studies for ESOPHAGEAL ADENOCARCINOMA (EAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy boosts Chemo-Radiation for esophageal cancer in major trial
Disease control OngoingThis phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy helps people with advanced esophageal cancer live longer or delay the cancer from coming back. About 700 participants who cannot have surgery will receive either pembrolizum…
Matched conditions: ESOPHAGEAL ADENOCARCINOMA (EAC)
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 17, 2026 10:04 UTC
-
French study tracks Real-World results of combo therapy for stomach cancer
Knowledge-focused OngoingThis study follows 208 adults in France who are already receiving nivolumab combined with chemotherapy as their first treatment for advanced or metastatic stomach, gastroesophageal junction, or esophageal cancers. The goal is to see how long patients live and how the disease resp…
Matched conditions: ESOPHAGEAL ADENOCARCINOMA (EAC)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated May 11, 2026 20:39 UTC